Vamil Divan

Stock Analyst at Guggenheim

(2.44)
# 882
Out of 5,383 analysts
284
Total ratings
Success rate
Average return
49 Stocks
Name Action PT Current % Upside Ratings Updated
JBIO Jade Biosciences
Upgrades: Buy
14
n/a n/a 1 Jun 16, 2025
SVRA Savara
Maintains: Buy
9 8
2.2 263.64% 1 May 28, 2025
AMGN Amgen
Assumes: Neutral
288
281.17 2.43% 1 May 20, 2025
ANIP ANI Pharmaceuticals
Reiterates: Buy
86 86
65.04 32.23% 11 May 12, 2025
VALN Valneva
Maintains: Buy
15 14
5.76 143.06% 1 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
214 216
186.79 15.64% 23 Apr 29, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
6.43 833.13% 1 Apr 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
115 115
78.76 46.01% 9 Apr 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
47 47
15.07 211.88% 8 Apr 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 15 Apr 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
31
17.32 78.98% 1 Mar 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
10 10
2.72 267.65% 3 Mar 20, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
n/a
n/a n/a 17 Mar 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
59 61
22.85 166.96% 5 Feb 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
101 101
101.58 -0.57% 6 Feb 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 5 Jan 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
7 4
n/a n/a 6 Dec 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
0.72 733.33% 1 Sep 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
55
n/a n/a 1 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
245 330
n/a n/a 7 Jan 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
19 20
9.28 115.52% 9 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
21 18
n/a n/a 2 Aug 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
26
0.66 3839.39% 2 Jun 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
35 40
n/a n/a 3 Jun 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 9
0.74 1116.22% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
13 2
n/a n/a 5 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
27 19
22.16 -14.26% 7 Aug 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
95 98
127.25 -22.99% 8 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 34
28.91 17.61% 7 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 10
1.72 481.4% 3 May 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
51 49
105.84 -53.7% 3 May 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
315 356
784.95 -54.65% 15 May 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 6
4.68 28.21% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
144 154
14.48 963.54% 9 Mar 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
15
9.29 61.46% 5 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 6 Dec 13, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 4
n/a n/a 6 Nov 8, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
11 19
n/a n/a 8 Sep 17, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
35
n/a n/a 13 Aug 5, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
n/a
n/a n/a 13 Jul 10, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
36 30
n/a n/a 4 May 21, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
161 155
n/a n/a 10 Mar 7, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
15
4 275% 4 Aug 15, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
58 61
46.81 30.31% 5 Jul 27, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
103
1.05 9709.52% 3 Jan 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
45 55
n/a n/a 1 Sep 19, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
66 120
n/a n/a 4 Dec 20, 2016